QβS100A9 VLP vaccine

The **QβS100A9 VLP vaccine** is a preclinical candidate immunotherapy developed to target the pro-inflammatory protein **S100A9 (calprotectin subunit)**, implicated in the pathogenesis of atherosclerosis and cancer metastasis[1][4]. It harnesses **virus-like particles (VLPs)** derived from bacteriophage Qβ, genetically engineered to display S100A9 peptide epitopes, stimulating an immune response with sustained endogenous antibody production. The vaccine is designed as either a soluble formulation or a single-dose, slow-release implant using **poly(lactic-co-glycolic acid) (PLGA)**. In animal models, vaccination reduces disease biomarkers (e.g., calprotectin, IL-1β, IL-6, MCP-1), mitigates aortic lesions, and suppresses lung tumor metastatic seeding[1][4]. The VLP platform acts both as antigen carrier and self-adjuvant, eliciting Th1/Th2 balanced adaptive immune responses. This approach offers long-term disease modification potential, aiming to replace chronic therapies like statins for cardiovascular disease or passive antibody therapies for metastatic cancer[1][4].

Brand names

QβS100A9 VLP vaccine

Other names

QβS100A9 vaccineQβ-S100A9 viral nanoparticle vaccineQβ VLP-S100A9 vaccine